Catherine Gilliss Net Worth

Catherine Gilliss biography

Dr. Catherine L. Gilliss Ph.D is an Independent Director of the Company. Dr. Gilliss serves as the Dean of the University of California, San Francisco School of Nursing following her appointment in September 2017. Dr. Gilliss previously served as Dean and the Helene Fuld Health Trust Professor of Nursing at the Duke University School of Nursing (2004-2014). While on sabbatical (2014-2015), she was a member of the inaugural cohort of fellows in the Stanford University Distinguished Careers Institute. From 1998 until 2004, she served as professor and the Dean at the Yale University School of Nursing. Dr. Gilliss earned her BSN from Duke, her MSN from The Catholic University of America and her PhD from the University of California, San Francisco, where she also completed postdoctoral studies. Our Board of Directors believes that Dr. Gilliss’ expertise and experience in the healthcare and nursing fields qualifies her to serve on our Board of Directors.

What is the salary of Catherine Gilliss?

As the Independent Director of Chimerix Inc, the total compensation of Catherine Gilliss at Chimerix Inc is $105,694. There are 9 executives at Chimerix Inc getting paid more, with Michael Sherman having the highest compensation of $2,644,630.

How old is Catherine Gilliss?

Catherine Gilliss is 71, he's been the Independent Director of Chimerix Inc since 2014. There are no older and 12 younger executives at Chimerix Inc.

What's Catherine Gilliss's mailing address?

Catherine's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.

Insiders trading at Chimerix Inc

Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex und Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.

What does Chimerix Inc do?

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Chimerix Inc executives and stock owners

Chimerix Inc executives and other stock owners filed with the SEC include:

• Michael Sherman,
  President, Chief Executive Officer, Director
• Michael Andriole,
  Chief Financial Officer, Chief Business Officer
• Michael Alrutz,
  Senior Vice President, General Counsel
• Michael A. Sherman,
  CEO, Pres & Director
• Michael T. Andriole M.B.A.,
  Chief Bus. Officer, Sec. & CFO
• Dr. Allen S. Melemed M.B.A., M.D.,
  Chief Medical Officer
• Martha Demski,
  Independent Chairman of the Board
• Patrick Machado,
  Independent Director
• Fred Middleton,
  Independent Director
• Robert Meyer,
  Independent Director
• Catherine Gilliss,
  Independent Director
• Edward Greissing,
  Independent Director
• Pratik Multani,
  Independent Director
• Dr. Joshua E. Allen,
  Chief Technology Officer of Imipridones
• Dr. Michael A. Alrutz,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michelle LaSpaluto,
  VP of Strategic Planning & Investor Relations
• Dr. Randall Lanier,
  Chief Science Officer
• Dr. Roy W. Ware,
  Chief Manufacturing & Technology Officer
• David Jakeman,
  Exec. Director of Fin. & Accounting and Principal Accounting Officer
• Michael D. Rogers,
  Chief Development Officer
• James Niedel,
  Director
• Ernest Mario,
  Director
• M Michelle Berrey,
  President and CEO
• Garrett Nichols,
  Chief Medical Officer
• John M Leonard,
  Director
• Ronald C Jr Renaud,
  Director
• James M Daly,
  Director
• Lisa Ricciardi,
  Director
• Timothy Wollaeger,
  Director
• Linda M Richardson,
  Chief Commercial Officer
• Ed Greissing,
  Director
• Victoria Vakiener,
  
• Leaf Ventures Ii, L.P. New,
  10% owner
• Venture Partners V, Lp Sand...,
  10% owner
• Venture Partners Vi Co Inve...,
  10% owner
• Rodman L Drake,
  Director
• Vii L P Canaan Partners Vii...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Kenneth I Moch,
  President and CEO
• Wende S Hutton,
  Director
• Venture Partners V, Lp Sand...,
  
• Arthur M Pappas,
  Director
• Venture Partners V, Lpsande...,
  
• Farah Champsi,
  Director
• Timothy W. Trost,
  SVP, CFO & Secretary
• Biopharma Partners Iii Lpal...,
  
• Pappas Life Science Venture...,
  
• Lisa Lynn Decker,
  
• Pharmaceuticals, Inc. Cantex,
  10% owner
• Marc D Kozin,
  
• David Jakeman,
  VP OF FINANCE AND ACCOUNTING
• Thomas J Riga,
  COO and CCO
• Allen S. Melemed,
  CHIEF MEDICAL OFFICER
• Michelle La Spaluto,
  CHIEF FINANCIAL OFFICER